Lifesci Capital Estimates Oculis' Q1 Earnings (NASDAQ:OCS)

Key Points

• LifeSci Capital cut its Q1 2026 EPS estimate for Oculis to ($0.46) (from ($0.40)) and projects FY2026 EPS of ($1.89), while retaining an Outperform rating and a $55 price target.
• Oculis reported Q1 EPS of ($0.51), missing the consensus of ($0.43) despite revenue beating estimates, and continues to show deeply negative margins and return on equity, highlighting biotech cash‑burn risk.
• Near‑term catalysts include the DIAMOND Phase 3 OCS‑01 readout in Q2 2026 and a Breakthrough Therapy designation for Privosegtor, and recent institutional accumulation plus analyst upgrades could materially re‑rate the stock if clinical results are positive.

Oculis Holding AG (NASDAQ:OCS - Free Report) - Lifesci Capital decreased their Q1 2026 earnings per share estimates for shares of Oculis in a report released on Wednesday, March 4th. Lifesci Capital analyst P. Dolezal now expects that the company will post earnings per share of ($0.46) for the quarter, down from their previous estimate of ($0.40). Lifesci Capital has a "Outperform" rating and a $55.00 price target on the stock. The consensus estimate for Oculis' current full-year earnings is ($2.09) per share. Lifesci Capital also issued estimates for Oculis' Q2 2026 earnings at ($0.47) EPS, Q3 2026 earnings at ($0.48) EPS, Q4 2026 earnings at ($0.49) EPS and FY2026 earnings at ($1.89) EPS.

Oculis (NASDAQ:OCS - Get Free Report) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.08). The company had revenue of $0.50 million for the quarter, compared to analysts' expectations of $0.14 million. Oculis had a negative net margin of 8,173.41% and a negative return on equity of 62.12%.

OCS has been the subject of a number of other research reports. Wall Street Zen upgraded Oculis from a "sell" rating to a "hold" rating in a research report on Saturday, November 15th. Stifel Nicolaus increased their price objective on shares of Oculis from $40.00 to $50.00 and gave the stock a "buy" rating in a research note on Wednesday. Weiss Ratings restated a "sell (d-)" rating on shares of Oculis in a research report on Thursday, January 22nd. HC Wainwright upped their target price on shares of Oculis from $42.00 to $44.00 and gave the company a "buy" rating in a report on Wednesday. Finally, Chardan Capital reiterated a "buy" rating and issued a $51.00 price target on shares of Oculis in a research report on Tuesday, November 11th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Oculis has an average rating of "Moderate Buy" and an average target price of $43.50.

Oculis Trading Up 0.1%

NASDAQ:OCS opened at $27.74 on Friday. The company has a 50 day simple moving average of $26.03 and a two-hundred day simple moving average of $21.49. The company has a market cap of $1.45 billion, a PE ratio of -12.22 and a beta of 0.29. The company has a current ratio of 5.96, a quick ratio of 4.47 and a debt-to-equity ratio of 0.01. Oculis has a 12 month low of $14.00 and a 12 month high of $30.68.

Institutional Trading of Oculis

Institutional investors and hedge funds have recently modified their holdings of the company. Bank of America Corp DE boosted its holdings in Oculis by 2.2% in the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company's stock worth $786,000 after buying an additional 878 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in shares of Oculis by 100.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company's stock valued at $40,000 after acquiring an additional 1,000 shares in the last quarter. Aventura Private Wealth LLC bought a new position in shares of Oculis in the fourth quarter worth about $80,000. Geode Capital Management LLC grew its position in shares of Oculis by 27.7% during the second quarter. Geode Capital Management LLC now owns 29,436 shares of the company's stock worth $571,000 after purchasing an additional 6,384 shares in the last quarter. Finally, Compagnie Lombard Odier SCmA raised its stake in Oculis by 10.6% during the 4th quarter. Compagnie Lombard Odier SCmA now owns 107,300 shares of the company's stock valued at $2,143,000 after purchasing an additional 10,300 shares during the period. 22.30% of the stock is currently owned by institutional investors.

Key Stories Impacting Oculis

Here are the key news stories impacting Oculis this week:

• Positive Sentiment: Privosegtor received Breakthrough Therapy designation for optic neuritis and Oculis is advancing registrational programs in optic neuropathies — a large addressable U.S. market (>$7B) if trials succeed. This is a material clinical/regulatory positive for OCS. Article Title
• Positive Sentiment: Topline readout for OCS-01 in diabetic macular edema (DIAMOND Phase 3) is on track for Q2 2026 — a near-term binary catalyst that could materially re‑rate the stock if positive. Article Title
• Positive Sentiment: Wall Street support increased: Needham and HC Wainwright raised price targets (to $40 and $44 respectively) and maintain buy ratings — these upgrades can attract investor interest and support higher valuations. Article Title
• Positive Sentiment: Significant institutional accumulation reported (multiple funds added large positions in Q4 2025), which can provide demand support into upcoming catalysts. Article Title
• Neutral Sentiment: Oculis is presenting at multiple investor conferences in March (Leerink Global Healthcare Conference, LifeSci Capital Biotech Forum) — increases management visibility and provides opportunities for Q&A but no direct clinical data. Article Title
• Neutral Sentiment: Company filed audited 2025 consolidated financial statements and MD&A with the SEC — increases transparency; separately, Oculis renewed a $100M ATM program (capital flexibility that can fund development but may dilute if used). Article Title
• Negative Sentiment: Quarterly results missed EPS estimates (reported ($0.51) vs. consensus ($0.43)); while revenue beat estimates, margins and ROE remain deeply negative — a reminder of biotech execution and cash‑burn risk until pivotal approvals. Article Title
• Negative Sentiment: Notifications show RSU vesting/settlement for a director — standard governance activity but adds modest share count pressure/short‑term dilution. Article Title

Oculis Company Profile

Oculis SA NASDAQ: OCS is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.